David Kabakoff

David S.
Kabakoff founded Salmedix, Inc. in 2001, where he worked as Chairman & Chief Executive Officer from 2001 to 2005, Amplimmune, Inc. in 2007, where he worked as Chairman, and Strategy Advisors LLC in 2001, where he worked as President in 2011.
Dr. Kabakoff also currently works at NextCure, Inc., as Chairman from 2015, Biotheranostics, Inc., as Director, Antiva Biosciences, Inc., as Director from 2015, RareCyte, Inc., as Director, Rainier Therapeutics, Inc., as Director from 2018, Dauntless 1, Inc., as Director, Dauntless Pharmaceuticals, Inc., as Director, Dauntless 2, Inc., as Director, Neurana Pharmaceuticals, Inc., as Director, Intrepida Bio, Inc., as Director, Sofinnova Investments, Inc., as Executive Advisor, and Healthquest Capital Management Co LLC, as Founding Senior Partner.
Dr. Kabakoff also formerly worked at Corvas International, Inc., as Chairman & Chief Executive Officer from 1989 to 1996, Spiros Development Corp II, Inc., as President & Chief Executive Officer, Cebix, Inc., as Non-Executive Chairman, Trius Therapeutics, Inc., as Chairman from 2006 to 2013, InterMune, Inc., as Independent Director from 2011 to 2014, Allylix, Inc., as Director, Principia Biopharma, Inc., as Director from 2016 to 2018, Avalon Pharmaceuticals, Inc., as Director from 2006 to 2009, Jewish Community Foundation of San Diego, as Treasurer & Director from 2012 to 2014, Castle Biosciences, Inc., as Independent Director from 2017 to 2021, Dura Pharmaceuticals, Inc., as Executive Vice President from 1996 to 2000, Hybritech, Inc., as Vice President-Research & Development from 1983 to 1989, and Lineagen, Inc., as Board Member.
Dr. Kabakoff received his undergraduate degree from Case Western Reserve University and doctorate degree from Yale University.